Meyka Pro banner
Sirnaomics Ltd.

Sirnaomics Ltd. Fundamental Analysis

2257.HKHKSE
HealthcareBiotechnology
HK$4.11
HK$0.41(9.07%)
Hong Kong Market opens in 16h 22m

Sirnaomics Ltd. Fundamental Analysis

Sirnaomics Ltd. (2257.HK) shows weak financial fundamentals with a PE ratio of -3.41, profit margin of -178.07%, and ROE of 1.92%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.28

Areas of Concern

ROE1.92%
Operating Margin-188.71%
Cash Position3.57%
Current Ratio0.40
We analyze 2257.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -16629.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-16629.6/100

We analyze 2257.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

2257.HK struggles to generate sufficient returns from assets.

ROA > 10%
-70.01%

Valuation Score

Excellent

2257.HK trades at attractive valuation levels.

PE < 25
-3.41
PEG Ratio < 2
-0.28

Growth Score

Weak

2257.HK faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

2257.HK shows balanced financial health with some risks.

Debt/Equity < 1
-0.94
Current Ratio > 1
0.40

Profitability Score

Weak

2257.HK struggles to sustain strong margins.

ROE > 15%
191.92%
Net Margin ≥ 15%
-178.07%
Positive Free Cash Flow
No

Key Financial Metrics

Is 2257.HK Expensive or Cheap?

P/E Ratio

2257.HK trades at -3.41 times earnings. This suggests potential undervaluation.

-3.41

PEG Ratio

When adjusting for growth, 2257.HK's PEG of -0.28 indicates potential undervaluation.

-0.28

Price to Book

The market values Sirnaomics Ltd. at -4.87 times its book value. This may indicate undervaluation.

-4.87

EV/EBITDA

Enterprise value stands at -4.40 times EBITDA. This is generally considered low.

-4.40

How Well Does 2257.HK Make Money?

Net Profit Margin

For every $100 in sales, Sirnaomics Ltd. keeps $-178.07 as profit after all expenses.

-178.07%

Operating Margin

Core operations generate -188.71 in profit for every $100 in revenue, before interest and taxes.

-188.71%

ROE

Management delivers $1.92 in profit for every $100 of shareholder equity.

1.92%

ROA

Sirnaomics Ltd. generates $-70.01 in profit for every $100 in assets, demonstrating efficient asset deployment.

-70.01%

Following the Money - Real Cash Generation

Operating Cash Flow

Sirnaomics Ltd. generates limited operating cash flow of $-10.57M, signaling weaker underlying cash strength.

$-10.57M

Free Cash Flow

Sirnaomics Ltd. generates weak or negative free cash flow of $-10.64M, restricting financial flexibility.

$-10.64M

FCF Per Share

Each share generates $-0.10 in free cash annually.

$-0.10

FCF Yield

2257.HK converts -16.66% of its market value into free cash.

-16.66%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.41

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.28

vs 25 benchmark

P/B Ratio

Price to book value ratio

-4.87

vs 25 benchmark

P/S Ratio

Price to sales ratio

685.82

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.94

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.40

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.92

vs 25 benchmark

ROA

Return on assets percentage

-0.70

vs 25 benchmark

ROCE

Return on capital employed

0.87

vs 25 benchmark

How 2257.HK Stacks Against Its Sector Peers

Metric2257.HK ValueSector AveragePerformance
P/E Ratio-3.4129.15 Better (Cheaper)
ROE191.92%438.00% Weak
Net Margin-17806.58%-11409.00% (disorted) Weak
Debt/Equity-0.940.78 Strong (Low Leverage)
Current Ratio0.405.14 Weak Liquidity
ROA-70.01%-21.00% (disorted) Weak

2257.HK outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Sirnaomics Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ